Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 9.54 INR
Change Today 0.00 / 0.00%
Volume 0.0
ORTL On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:14 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

ortin laboratories ltd (ORTL) Snapshot

Open
10.40
Previous Close
9.54
Day High
10.40
Day Low
9.40
52 Week High
09/23/14 - 19.00
52 Week Low
03/27/15 - 7.55
Market Cap
161.6M
Average Volume 10 Days
34.4K
EPS TTM
0.70
Shares Outstanding
16.9M
EX-Date
09/24/13
P/E TM
13.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for ORTIN LABORATORIES LTD (ORTL)

Related News

No related news articles were found.

ortin laboratories ltd (ORTL) Related Businessweek News

No Related Businessweek News Found

ortin laboratories ltd (ORTL) Details

Ortin Laboratories Limited manufactures and sells drug intermediates and pharmaceuticals in India. The company offers a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti diabetics, anti allergics, anti anginal and cardio vascular, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti biotics-quinolones, anti biotic-pencillins, antifungal, cephalosporins, and macrolides. The company’s formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodic, calcium preparations, iron preparations, anti arthritic drugs, protein supplements, enzymes and vitamins, psychiatry, appetizers, gynaec, and anti retrovirals. In addition, it provides active pharmaceutical ingredients (APIs) comprising anti retro viral, anti diabetics, analgesics and antipyretics, anti biotic, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company offers services in the areas of process development, process characterization, analytical research and development, assay development, and product characterization; and diagnostic services, including development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs. Ortin Laboratories Limited was founded in 1986 and is headquartered in Hyderabad, India.

Founded in 1986

ortin laboratories ltd (ORTL) Top Compensated Officers

Chairman, Managing Director and Compliance Of...
Total Annual Compensation: 1.5M
Joint Managing Director and Director
Total Annual Compensation: 960.0K
Whole Time Director and Member of Audit Commi...
Total Annual Compensation: 1.5M
Whole-Time Director
Total Annual Compensation: 1.1M
Whole Time Director
Total Annual Compensation: 960.0K
Compensation as of Fiscal Year 2014.

ortin laboratories ltd (ORTL) Key Developments

Ortin Laboratories Ltd., Board Meeting, Mar 31, 2015

Ortin Laboratories Ltd., Board Meeting, Mar 31, 2015. Agenda: To consider the appointment of CFO; to consider appointment of women director; and to consider the appointment of secretarial auditor.

Ortin Laboratories Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Ortin Laboratories Ltd. announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales of INR 48.144 million compared to INR 94.112 million reported a year ago. Profit from operations before other income, finance costs and exceptional items was INR 12.679 million compared to INR 9.388 million reported a year ago. Profit from ordinary activities before tax was INR 1.901 million compared to INR 1.123 million reported a year ago. Net profit was INR 0.555 million or INR 0.03 per basic and diluted share before and after extraordinary items compared to INR 0.65 million or INR 0.04 per basic and diluted share before and after extraordinary items reported a year ago. For the nine months, the company reported net sales of INR 222.246 million compared to INR 426.587 million reported a year ago. Profit from operations before other income, finance costs and exceptional items was INR 45.142 million compared to INR 41.271 million reported a year ago. Profit from ordinary activities before tax was INR 17.915 million compared to INR 16.436 million reported a year ago. Net profit was INR 11.360 million or INR 0.67 per basic and diluted share before and after extraordinary items compared to net profit of INR 10.87 million or INR 0.64 per basic and diluted share before and after extraordinary items reported a year ago.

Ortin Laboratories Ltd., Board Meeting, Feb 14, 2015

Ortin Laboratories Ltd., Board Meeting, Feb 14, 2015. Agenda: To consider unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORTL:IN 9.54 INR 0.00

ORTL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ORTL.
View Industry Companies
 

Industry Analysis

ORTL

Industry Average

Valuation ORTL Industry Range
Price/Earnings 13.4x
Price/Sales 0.4x
Price/Book 0.7x
Price/Cash Flow 6.0x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORTIN LABORATORIES LTD, please visit www.ortinlabsindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.